OpenAlex
PricingAboutJobs
Log inGet started
Work

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

HTML

Year: 2018
Type: article
Study design: Clinical Trial
Source: The Lancet Respiratory Medicine
DOI: 10.1016/s2213-2600(18)30151-6
Authors: Luana Calabrò, Aldo Morra, Diana Giannarelli, Giovanni Amato, Armida D'Incecco, Alessia Covre, Arthur Lewis, Marlon C Rebelatto, Riccardo Danielli, Maresa Altomonte, Anna Maria Di Giacomo, Michele Maio
Institutions: University of Siena, Instituto Nazionale Tumori Regina Elena
Language: English

Topic: Occupational and environmental lung diseases
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Keywords: malignant pleural mesothelioma, peritoneal mesothelioma, tremelimumab, durvalumab, CTLA-4 blockade, PD-L1 blockade, immune checkpoint inhibitors, combination immunotherapy, immune-related adverse events, first-line therapy, second-line therapy, maintenance therapy
SDG: Good health and well-being

Open Access status: closed

Funder: Tumori Foundation
OpenAlex ID: W2801062708
FWCI: 24.4
Cites: 30
Cited by: 229
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Supporters
Legal
Privacy
Accessibility
Terms